Cardiovascular Disease: The Other Face of Diabetes

Despite glycemic control, evidence suggests that mortality and morbidity remain high in diabetes. Regulatory agencies deem, therefore, additional safety trials necessary for the approval of new antidiabetic drugs. Nevertheless, markers of cardiovascular risk, which can be used as response predictors...

Full description

Saved in:
Bibliographic Details
Published inCPT: pharmacometrics and systems pharmacology Vol. 2; no. 10; pp. 1 - 4
Main Authors Vlasakakis, G, Della Pasqua, O
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.10.2013
Nature Publishing Group
Subjects
Biomarkers
Blood pressure
Cardiovascular disease
Diabetes
Glucose
Health risk assessment
Hemoglobin
Homeostasis
Hyperglycemia
Insulin resistance
Lipids
Lipoproteins
Metabolic syndrome
Mortality
Online AccessGet full text

Cover

More Information
Summary:Despite glycemic control, evidence suggests that mortality and morbidity remain high in diabetes. Regulatory agencies deem, therefore, additional safety trials necessary for the approval of new antidiabetic drugs. Nevertheless, markers of cardiovascular risk, which can be used as response predictors, are not available. In contrast with current efforts on further understanding of glucose–insulin homeostasis, a model‐based approach is required to assess the correlation between hyperglycemia and cardiometabolic phenotypes, enabling prediction of the underlying cardiovascular risk. CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e81; doi:10.1038/psp.2013.57; advance online publication 23 October 2013
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2163-8306
2163-8306
DOI:10.1038/psp.2013.57